35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the Notes Tab. 35 USC 112 (f)*: Identifying Limitations.
Incorporation by Reference
1 35 U.S.C nd paragraph Julie Burke TC1600 QAS
G & B Seminar 2006 Claim Drafting Ken Moore.
04/08/ U.S.C. § 112 Supplementary Examination Guidelines Office of Patent Legal Administration United States Patent and Trademark Office.
1 35 U.S.C. § 112 Supplementary Examination Guidelines Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting September 13, 2011 Kathleen K.
1 1 1 AIPLA American Intellectual Property Law Association Standard for Indefiniteness– Nautilus, Inc. v. Biosig Instruments, Inc. Stephen S. Wentsler.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting October 8, 2002 William F. Smith Administrative Patent Judge Board of Patent Appeals.
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Filing Compliant Reexam Requests Andy Kashnikow SPE, Central Reexamination Unit Andy Kashnikow SPE, Central Reexamination Unit June, 2010.
Community Patent Robert Clarke – Deputy Director Office of Patent Legal Administration
Memorandum - 35 U.S.C. 112, Second and Sixth Paragraphs Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
John B. Pegram Fish & Richardson P.C. New York “Divided” or “Joint” Infringement.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Greg H. Gardella Ex Parte and Inter Partes Reexamination Tactics AIPLA 2010 Winter Institute.
Safekeeping of 35 U.S.C. 156 Extensions
DOE/PHE II Patent Law. United States Patent 4,354,125 Stoll October 12, 1982 Magnetically coupled arrangement for a driving and a driven member.
Examining Functional Claim Limitations: Focus on Computer/Software-related Claims
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
2 23,503 hours in FY 2013, compared with 21,273 hours in FY ,651 interview hours in FY 13 have been charged through the AFCP program. Interview.
1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Anthony Caputa, Ph.D. Technology Center Practice Specialist TC 1600.
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Patent Prosecution Luncheon March White House Patent Reform: Executive Actions Draft rule to ensure patent owners accurately record and regularly.
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
1 EXAMINER’S REASONS FOR ALLOWANCE Samson Helfgott Director of Patents KMZ Rosenman New York, N.Y. January, To Respond, or not to Respond?
Routine Optimization Jean Witz, tQAS, TC
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Reexamination at the USPTO Robert A. Clarke Deputy Director Office of Patent Legal Administration USPTO Robert A. Clarke Deputy Director Office of Patent.
Discussion of Unpaid Claim Estimate Standard  Raji Bhagavatula  Mary Frances Miller  Jason Russ November 13, 2006 CAS Annual Meeting San Francisco,
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 1 Enhancing Compact Prosecution RCEs and BPAI Appeals The Frequency and.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
QualityDefinition.PPACMeeting AdlerDraft 1 1 Improving the Quality of Patents Marc Adler PPAC meeting June 18, 2009.
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
UNITED STATES PATENT AND TRADEMARK OFFICE
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
“The Squeeze” Art and Enablement Together Yvonne L. Eyler, SPE AU 1646.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association U.S. Implementation of the Hague Agreement For Designs John (Jack) J. Penny, V Event.
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Regulation Inside Government: Reducing Administrative Burden Issues and Approaches Case Study: Canada OECD Workshop Mexico City – March 14-15, 2006 Gilles.
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
Chapter 7 Part 1. 2 Judicial Review "The rules governing judicial review have no more substance at the core than a seedless grape." This is a very unsettling.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
LYDON - TERMINAL DISCLAIMERS1 Terminal Disclaimer (TD) A Terminal Disclaimer states that the patent –will expire on the same date as a related.
10/13/081 PARK - SPEC SAME IN APP & PAT The Specification: Application v. Issued Patent Why is the specification in the application almost exactly identical.
Introduction to Intellectual Property Class of Sept
July 13, 2016 Patent Technology Centers 3600 & 3700 Customer Partnership 112(b) Discussion Ashok K. Mannava
Objectives of WHO's collaboration with NGOs
Tim Saulsbury -- Continuations in Part
Processes Which Employ Non-Obvious Products
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
35 U.S.C. § 112 Supplementary Examination Guidelines Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting September 13, 2011 Kathleen.
Prosecution Luncheon Patent March 2017
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Written Description Design Law 2018 Dan Gajewski October 24, 2018.
Update and Practical Considerations
PTAB Litigation 2016 Part 4 – The Institution Decision
Presentation transcript:

35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark Office

1/26/092 Memorandum signed by John Love, Deputy Commissioner for Patent Examination Policy (DCPEP) on September 2, 2008: “Indefiniteness rejections under 35 U.S.C. 112, second paragraph” 35 U.S.C. 112, Second Paragraph Examination Memorandum

10/12/20153 Purpose: Remind the Examining Corps about the appropriate use of indefiniteness rejections and the public policy rationale for requiring definite claim language. Triggering Event: The Federal Circuit articulated the following: “...the patent drafter is in the best position to resolve the ambiguity in the patent claims, and it is highly desirable that patent examiners demand that applicants do so in appropriate circumstances...” See Halliburton Energy Services, Inc. v. M-I LLC, 514 F.3d 1244, 1255 (Fed. Cir. 2008). The Federal Circuit later re-emphasized this same point in a more recent decision, Lucent Technologies, Inc. v. Gateway, Inc., 543 F.3d 710 (Fed. Cir. 2008). 35 U.S.C. 112, Second Paragraph Examination Memorandum

10/12/20154 Issues discussed in the Examination Memorandum Resolve confusion over January 17, 2003 DCPEP memorandum regarding indefiniteness rejections in light of the Festo decision, which was misconstrued as discouraging the use of 35 U.S.C. 112, second paragraph rejections during examination. Discuss and clarify the appropriate use of indefiniteness rejections under 35 U.S.C. 112, second paragraph, based upon a lack of a clear and precise definition of claim terms, i.e. Halliburton’s ambiguity issue. Examiner’s are encouraged to make such rejections when appropriate. (See MPEP ) Discuss and clarify the appropriate use of indefiniteness rejections under 35 U.S.C. 112, second paragraph, based upon a lack of proper antecedent basis in the claims. Examiner’s are encouraged to make such rejections when appropriate. (See MPEP (e)) 35 U.S.C. 112, Second Paragraph Examination Memorandum

10/12/20155 Examination guidance delineating appropriateness when issuing indefiniteness rejections for imprecise claim term definitions: An indefiniteness rejection is generally proper if: –Applicant discloses a definition in the specification, but the definition is not clear and precise to one of ordinary skill in the art. –Applicant’s usage of a term in the claims is inconsistent with their disclosure regarding the term in the specification. –Applicant uses a claim term that is not used or defined in the specification, and the meaning is not discernible. An indefiniteness rejection is generally not proper if: –Applicant clearly discloses any definition or special meaning of a claim term to one of ordinary skill in the art. –Applicant’s usage of a term in the claims is consistent with their disclosure regarding the term in the specification. –Applicant uses a claim term that is not used or defined in the specification, but the meaning is discernible to one of ordinary skill in the art. (Note: An objection under 37 CFR 1.75(d)(1) maybe appropriate) 35 U.S.C. 112, Second Paragraph Examination Memorandum

10/12/20156 Examination guidance delineating appropriateness when issuing indefiniteness rejections for lack of antecedent basis: An indefiniteness rejection is generally appropriate if: –The lack of explicit antecedent basis makes the claim unclear to one of ordinary skill in the art as to whether or not applicant is further limiting a claim limitation or introducing a new claim limitation. An indefiniteness rejection is generally not appropriate if: –The scope of the claim is reasonably ascertainable by one of ordinary skill despite a lack of explicit antecedent basis. 35 U.S.C. 112, Second Paragraph Examination Memorandum

10/12/20157 Practitioner Relevance: “... the patent drafter is in the best position to resolve the ambiguity in the patent claims... so that the patent can be amended during prosecution rather than attempting to resolve the ambiguity in litigation.” Halliburton at U.S.C. 112, Second Paragraph Examination Memorandum

10/12/20158 Questions?

10/12/20159 Robert Clarke (571) Contact Information